GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (NAS:SNSS) » Definitions » Quick Ratio

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Quick Ratio : 6.69 (As of Dec. 2020)


View and export this data going back to 2005. Start your Free Trial

What is Sunesis Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Sunesis Pharmaceuticals's quick ratio for the quarter that ended in Dec. 2020 was 6.69.

Sunesis Pharmaceuticals has a quick ratio of 6.69. It generally indicates good short-term financial strength.

The historical rank and industry rank for Sunesis Pharmaceuticals's Quick Ratio or its related term are showing as below:

SNSS's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.53
* Ranked among companies with meaningful Quick Ratio only.

Sunesis Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Sunesis Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Quick Ratio Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.95 2.60 1.34 3.86 6.69

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.86 3.32 2.65 7.74 6.69

Competitive Comparison of Sunesis Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Sunesis Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunesis Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunesis Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Sunesis Pharmaceuticals's Quick Ratio falls into.



Sunesis Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Sunesis Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Quick Ratio (A: Dec. 2020 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(22.144-0)/3.31
=6.69

Sunesis Pharmaceuticals's Quick Ratio for the quarter that ended in Dec. 2020 is calculated as

Quick Ratio (Q: Dec. 2020 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(22.144-0)/3.31
=6.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunesis Pharmaceuticals  (NAS:SNSS) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Sunesis Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.
Executives
Steve Carchedi director 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Nicole Onetto director 58 S SERVICE RD, MELVILLE NY 11747
Henry Ward Wolff director 6701 KAISER DRIVE, FREMONT CA 94555
Steven B Ketchum director 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
James W Young director
Homer L Pearce director 84 CLIFDEN, ZIONSVILLE IN 46077
Dayton Misfeldt director, officer: See Remarks C/O BAY CITY CAPITAL LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
David C Stump director
Tina Gullotta officer: VP, Finance SUNESIS PHARMACEUTICALS,INC, 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William P. Quinn officer: See Remarks SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Judith A. Fox officer: See Remarks SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Aisling Capital Iv, Lp 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms 10 percent owner 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Aisling Capital Partners Iv Llc 10 percent owner 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Headlines

From GuruFocus

Sunesis Pharmaceuticals Provides Corporate Update

By Marketwired Marketwired 07-08-2020

Sunesis Announces Proposed Public Offering of Common Stock

By Marketwired Marketwired 07-29-2020